Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Shanghai University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS

Xin Xin’s academic journey is rooted in the integration of Traditional Chinese Medicine (TCM) with Western medicine, particularly focusing on reproductive health and gynecology. He obtained a Bachelor of Science in Chinese Medicine from Shandong University of Traditional Chinese Medicine. His academic foundation continued to expand as he pursued an MD in Gynecology of Traditional Chinese Medicine, further honing his expertise in reproductive diseases. Xin is currently working towards his PhD in Clinical Chinese Medicine Integrated with Western Medicine at Shanghai University of Traditional Chinese Medicine, under the guidance of Advisor Jinfu Zhang.

💼 PROFESSIONAL ENDEAVORS

Xin Xin’s professional career is centered on bridging the gap between traditional and modern medical approaches. He is particularly involved in the clinical and mechanistic research of reproductive diseases, with a primary focus on polycystic ovary syndrome (PCOS). His work aims to enhance diagnostic methods and treatment approaches through a combined understanding of TCM and Western medicine. Xin has contributed significantly to clinical studies and investigations, with his academic path guided by prominent scholars in the field, including Dr. Fang Lian and Dr. Haicui Wu during his MD program at Shandong University.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Xin Xin’s research is notable for its emphasis on the pathogenesis, diagnosis, and treatment of reproductive diseases, with a particular focus on PCOS. He has undertaken several groundbreaking projects, one of which explores the expression of long non-coding RNAs (lncRNA) in follicular fluid exosomes of patients with obesity and PCOS using high-throughput sequencing technology. This research represents an effort to better understand the molecular mechanisms behind PCOS and to uncover novel biomarkers for early detection and intervention.

Another area of Xin’s research explores the role of Bone Morphogenetic Protein 6 (BMP6) in regulating Pentraxin 3 expression in human granulosa lutein cells in women with PCOS. His studies are pivotal in uncovering molecular markers and pathways that could lead to more effective therapeutic strategies.

🌟 IMPACT AND INFLUENCE

Xin Xin’s work has garnered attention within the scientific community due to his innovative approach of combining traditional Chinese medicine with Western medical techniques. His research aims to contribute to the development of a more holistic and comprehensive understanding of reproductive diseases. By investigating both the molecular and clinical aspects of PCOS, Xin is pushing boundaries in reproductive health research. His work has the potential to change how clinicians approach the treatment of polycystic ovary syndrome, a condition that affects millions of women worldwide.

📑 ACADEMIC CITES

Although his research is relatively recent, Xin Xin’s work is beginning to attract attention in the academic community. His publications on the expression of lncRNAs and BMP6 in PCOS are contributing to the growing body of knowledge on this common reproductive disorder. These publications are expected to increase in citations as they influence future studies and clinical approaches. His articles, including “Exploring lncRNA expression in follicular fluid exosomes of patients with obesity and polycystic ovary syndrome” (2024), and “Bone Morphogenetic Protein 6 Induces Downregulation of Pentraxin 3 Expression in Human Granulosa Lutein Cells in Women With Polycystic Ovary Syndrome” (2024), are already making a mark in reproductive health research.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Xin Xin is poised to continue his impactful contributions to the field of reproductive medicine. With a focus on integrating TCM with Western medical practices, his future research may lead to the development of novel therapeutic modalities for PCOS and other reproductive diseases. He is likely to remain an influential figure in the field of gynecology, particularly in areas that explore the intersections between traditional and modern approaches to healthcare. His research has the potential to influence both clinical practices and medical education, paving the way for new, more integrated methods of treating complex reproductive health conditions.

In the coming years, Xin Xin’s work will likely expand into further clinical trials and studies, contributing to the refinement of treatments for women with PCOS, and potentially providing a more personalized and effective approach to reproductive medicine globally.

✨Conclusion:

Xin Xin’s academic and professional journey stands as a testament to the growing importance of integrating traditional and modern medical practices in addressing complex health conditions. His dedicated research in reproductive medicine, particularly focusing on polycystic ovary syndrome (PCOS), has already made valuable contributions to understanding its pathogenesis and improving diagnostic and therapeutic methods. By exploring innovative molecular mechanisms and combining high-throughput sequencing technology with traditional Chinese medicine, Xin is laying the groundwork for a more holistic approach to treating reproductive diseases.

📊🔬NOTABLE PUBLICATION:
  • Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching
    • Authors: Dong, L., Lian, F., Wu, H., Yu, X., Xin, X.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2022

 

  • The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2023

 

  • Effect of human chorionic gonadotropin injection before frozen-thawed embryo transfer: A retrospective cohort study
    • Authors: Xin, X., Dong, L., Guan, L., Li, J., Lian, F.
    • Journal: Medicine (United States)
    • Year: 2023

 

  • Clinical Efficacy and Mechanism of Erzhi Tiangui Prescription in Treatment of Patients with Repeated Implantation Failure of Kidney Deficiency Syndrome Based on sPD-1 and Th17/Treg Cytokines
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: Chinese Journal of Experimental Traditional Medical Formulae
    • Year: 2023

 

  • Total knee arthroplasty in patients with Klippel Trenaunay syndrome and knee osteoarthritis: A case report and a literature review
    • Authors: Li, J., Lv, G., Han, Z., Xin, X.
    • Journal: Medicine (United States)
    • Year: 2024

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Nankai University | China

Author Profile

Scopus

Orcid ID

📚 Prof. Tao Sun: Innovator in Oncology and Drug Development

🎓Position:

  • Professor and Doctoral Supervisor, College of Pharmacy, Nankai University, China 🎓

🌟Titles and Awards:

  • National Youth Talent 🌟
  • Winner of the Tianjin Distinguished Youth Scholar 🏆

🔬Research Focus:

  • Molecular mechanisms of malignant tumors 🧬
  • Drug development 💊
  • Pharmacology 🔬

📄Publications:

  • Over 40 papers in prestigious journals, including Advanced Materials, Science Translational Medicine, Hepatology, and Cancer Research, as the first or corresponding author. 📄

📜Patents and Approvals:

  • More than 20 authorized patents 📜
  • 3 new drug clinical approvals ✅

🧪Research Leadership:

  • Principal investigator of 8 major scientific research projects, including Major National Science and Technology Projects and general projects of the National Natural Science Foundation of China. 🧪

🥇Achievements in Education:

  • Instructed students to win the Gold Award in the China International College Students’ “Internet+” Innovation and Entrepreneurship Competition 🥇
  • Recipient of the “Top Ten Award of Scholarly Mentor and Beneficial Friend” at Nankai University 🎖
  • Second Prize winner of the Nankai University Teaching Achievement Award 🥈

💊Summary:

  • Prof. Tao Sun is a distinguished scholar and innovator at Nankai University, renowned for his contributions to oncology, drug development, and pharmacology. His prolific research, numerous patents, and leadership in significant scientific projects underscore his impact in the field. As an educator, he has been instrumental in guiding students to achieve excellence, earning recognition for his mentorship and teaching achievements. 🌟🔬💊

 

📊🔬Notable Publication:

 

Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1

  • Authors: Cai, S., Bi, Z., Bai, Y., … Liu, H., Yang, C.
    Journal: Frontiers in Oncology
  • Year: 2020

 

Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin

  • Authors: Meng, J., Han, J., Wang, X., … Liu, H., Sun, T.
    Journal: Pharmacological Research
  • Year: 2023

 

Correction: Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma

  • Authors: Han, J., Meng, J., Chen, S., … Sun, T., Yang, C.
    Journal: Cancer Research
  • Year: 2019

Mr. Yang Gao | Cholangiocarcinoma | Best Researcher Award

Mr. Yang Gao | Cholangiocarcinoma | Best Researcher Award

Tongji Medical College Huazhong University of Science and Technology | China

Author Profile

Scopus

📘 Dr. Yang Gao: A Dedicated Leader in Hepatobiliary Oncology Research

Full Name: Yang Gao

Gender: Male

Designation: Attending Doctor; Lecturer

Department: Department of Hepatobiliary Surgery

Institution/Organization: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Qualification: Doctor (MD, PhD)

Area of Specialization: Hepatobiliary Oncology and Cancer

Sub Division: Oncology Therapeutics and Novel Approaches

Date of Birth: October 25, 1987

Onboard Date: July 1, 2018

Total Experience:

  • Work: 5 years
  • Doctor: 3 years
  • Master: 3 years
  • Bachelor: 5 years

Contact Information:

🎓 Education and Training

  • 2015.09-2018.06: MD, PhD in Hepatobiliary Surgery from Tongji Medical College, Huazhong University of Science and Technology
  • 2012.09-2015.06: Master’s in Hepatobiliary Surgery from Tongji Medical College, Huazhong University of Science and Technology
  • 2007.09-2012.06: Bachelor’s in Clinical Medicine from Shandong Second Medical University

🏥 Professional Experience

2018.07 – Present: Attending Physician and Lecturer at the Affiliated Union Hospital of Tongji Medical College, Huazhong University of Science and Technology.

  • Proficient in surgical treatments for benign and malignant tumors of the liver and gallbladder, including gallstones.
  • Expert in minimally invasive laparoscopic surgery, especially for liver cancer, anatomical liver resection surgery, and complex biliary surgeries.
  • Skilled in the comprehensive treatment of hepatocellular carcinoma and biliary tract cancer, including intervention, targeting, and immunotherapy.

📊 Research, Innovations, and Extensions

  • Research Projects Completed and Ongoing: 6
  • Citation Index in Scopus/Web of Science/PubMed: 61
  • Total Project Cost: $414,000 USD
  • Patents: 5 published and under process
  • Journals Published (SCI and SCIE index): 12
  • Journals Published (Scopus/Web of Science/PubMed index): 13
  • Countries Visited for Research: 1
  • Cumulative Impact Factor (last 3 years): 55
  • H-index: 5
  • Invited Speaker/Resource Person: 1
  • Member of Professional Bodies: 10

🏆 Awards and Recognitions

  • Total Number of Awards and Recognitions: 1
  • Award Category: Best Researcher Award

🌐 Contribution to Research & Development, Innovations, and Extension Activities On Cholangiocarcinoma

Dr. Yang Gao has significantly contributed to the field of Tumor Research & Development, Innovations, and Extension Activities. His work focuses on advancing the understanding of tumor biology, therapeutic interventions, and patient care outcomes, particularly in hepatobiliary malignancies. Dr. Gao collaborates with interdisciplinary teams to discover novel biomarkers, therapeutic targets, and treatment modalities aimed at improving patient outcomes and quality of life.

Dr. Gao has played a pivotal role in translating research findings into clinical practice by fostering partnerships with industry stakeholders, academic institutions, and healthcare providers. His efforts have led to the development and implementation of cutting-edge technologies and treatment approaches in oncology.

Moreover, Dr. Gao actively engages in extension activities to disseminate knowledge and promote cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the information and resources needed to combat cancer effectively. His dedication to cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

📜 Personal and Research Proofs

  • Institute ID Number: 2018XH0171
  • Certificate Number (Education Proof): 1048722018100647
  • Passport Number: E28938966
  • Government ID: 370181198710251116

Declaration

Dr. Yang Gao, authenticate that to the best of my knowledge, the information given in this form is correct and complete. If any material information is found to be concealed, my application shall be summarily terminated without notice. I have read and agree to the terms and conditions and other policies of the International Research Awards.

Notable Publication

    • Authors: Yang Gao, et al.
    • Journal: Journal of Hepatology Research
    • Volume: 35
    • Year: 2021

 

 

    • Authors: Yang Gao, et al.
    • Journal: Cancer Research
    • Volume: 80
    • Year: 2022

 

    • Authors: Yang Gao, et al.
    • Journal: Annals of Surgery
    • Volume: 270
    • Year: 2021

 

    • Authors: Yang Gao, et al.
    • Journal: International Journal of Surgery
    • Volume: 76
    • Year: 2020